Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Therese Standal

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|June 14, 2023
The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymesMartin Kastnes, Kristin Roseth Aass, Siri Anshushaug Bouma, et al.
Blood|September 28, 2002
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsTherese Standal, Carina Seidel, Øyvind Hjertner, et al.
British Journal of Haematology|January 11, 2005
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survivalNiels Frost Andersen, Therese Standal, Johan Lanng Nielsen, et al.
European Journal of Haematology|August 20, 2013
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatmentTobias Schmidt Slørdahl, Tinneke Denayer, Siv Helen Moen, et al.
Plos One|October 8, 2015
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 TherapyAnne-Marit Sponaas, Neda Nejati Moharrami, Emadoldin Feyzi, et al.
Cell Death Discovery|February 20, 2021
Smac-mimetics reduce numbers and viability of human osteoclastsIngrid Nyhus Moen, Marita Westhrin, Erling Håland, et al.
British Journal of Haematology|November 20, 2002
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapyCarina Seidel, Stig Lenhoff, Sigmund Brabrand, et al.
Frontiers in Immunology|March 6, 2023
IL-32 is induced by activation of toll-like receptors in multiple myeloma cellsKristin Roseth Aass, Synne Stokke Tryggestad, Robin Mjelle, et al.
Biomaterials Advances|February 25, 2023
The effects of surface treatments on electron beam melted Ti-6Al-4V disks on osteogenesis of human mesenchymal stromal cellsKristin S Ødegaard, Marita Westhrin, Abdulla Bin Afif, et al.
Frontiers in Immunology|March 8, 2021
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?Anne Marit Sponaas, Anders Waage, Esten N Vandsemb, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|June 14, 2023
The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymesMartin Kastnes, Kristin Roseth Aass, Siri Anshushaug Bouma, et al.
Blood|September 28, 2002
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsTherese Standal, Carina Seidel, Øyvind Hjertner, et al.
British Journal of Haematology|January 11, 2005
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survivalNiels Frost Andersen, Therese Standal, Johan Lanng Nielsen, et al.
European Journal of Haematology|August 20, 2013
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatmentTobias Schmidt Slørdahl, Tinneke Denayer, Siv Helen Moen, et al.
Plos One|October 8, 2015
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 TherapyAnne-Marit Sponaas, Neda Nejati Moharrami, Emadoldin Feyzi, et al.
Cell Death Discovery|February 20, 2021
Smac-mimetics reduce numbers and viability of human osteoclastsIngrid Nyhus Moen, Marita Westhrin, Erling Håland, et al.
British Journal of Haematology|November 20, 2002
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapyCarina Seidel, Stig Lenhoff, Sigmund Brabrand, et al.
Frontiers in Immunology|March 6, 2023
IL-32 is induced by activation of toll-like receptors in multiple myeloma cellsKristin Roseth Aass, Synne Stokke Tryggestad, Robin Mjelle, et al.
Biomaterials Advances|February 25, 2023
The effects of surface treatments on electron beam melted Ti-6Al-4V disks on osteogenesis of human mesenchymal stromal cellsKristin S Ødegaard, Marita Westhrin, Abdulla Bin Afif, et al.
Frontiers in Immunology|March 8, 2021
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?Anne Marit Sponaas, Anders Waage, Esten N Vandsemb, et al.
Pageof 5